Cytokinetics, Inc. – Value Analysis (NASDAQ:CYTK) : July 31, 2017

Capitalcube gives Cytokinetics, Inc. a score of 82.

Our analysis is based on comparing Cytokinetics, Inc. with the following peers – GTx, Inc., ARCA biopharma, Inc., Ligand Pharmaceuticals Incorporated, Trevena, Inc., Acorda Therapeutics, Inc., Eiger BioPharmaceuticals, Inc., Array BioPharma Inc., ArQule, Inc. and Amgen Inc. (GTXI-US, ABIO-US, LGND-US, TRVN-US, ACOR-US, EIGR-US, ARRY-US, ARQL-US and AMGN-US).

Investment Outlook

Cytokinetics, Inc. has a fundamental score of 82 and has a relative valuation of NEUTRAL.

Fundamental Score

Access our research and ratings on Cytokinetics, Inc.

Company Overview

  • Considering peers, relative outperformance over the last year and the last month suggest a leading position.
  • It currently trades at a Price/Book ratio of (7.25).
  • CYTK-US outperforms its peers with a relatively high operating performance and the market also expects faster growth relative to its peers
  • CYTK-US has a successful operating model with relatively high net profit margins and asset turns.
  • The company’s year-on-year change in revenues and earnings are better than the median among its peer group.
  • Over the last five years, CYTK-US‘s return on assets has improved from median to better than the median among its peers, suggesting the company has found relative operating advantages.
  • Compared with the peers chosen, CYTK-US has had faster revenue growth in prior years and a current P/E ratio that suggests faster growth in the future suggesting superior growth expectations.
  • The company’s level of capital investment suggests it might be under-investing in a business with above median returns.
  • CYTK-US‘s operating performance may not allow it to raise additional debt.

Access our research and ratings on Cytokinetics, Inc.

Leverage & Liquidity

CYTK-US would seem to have a hard time raising additional debt.

  • With debt at 25.92% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 22.01%), and relatively tight interest coverage level of 0.56x, CYTK-US would have a hard time raising much additional debt.
  • Of the 9 chosen peers for the company, only 7 of the stocks have an outstanding debt balance. Companies with no debt include GTXI-US and ABIO-US.

CYTK-US has moved to a relatively low liquidity from an Quick & Able profile at the recent year-end.

  • CYTK-US‘s interest coverage is greater than (but within one standard deviation of) its five-year average interest coverage of -4,850.47x.
  • The decrease in its interest coverage to 0.56x from 5.26x (in 2016) was also accompanied by a decrease in its peer median during this period to -0.01x from 4.47x.
  • CYTK-US‘s debt-EV is its highest relative to the last five years and compares to a low of 0% in 2014.
  • The increase in its debt-EV to 25.92% from 8.13% (in 2016) was also accompanied by an increase in its peer median during this period to 22.01% from 9.51%.
  • Relative to peers, debt-EV rose 5.29 percentage points (and is now higher than its peer median). Unlike the peer median, it is also above the 25% leverage benchmark.

Access the detailed analysis for Cytokinetics, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
GTx, Inc. 0 3.94 No interest exp 999
ARCA biopharma, Inc. 0 7.88 No interest exp 999
Ligand Pharmaceuticals Incorporated 10.53 0.77 3.28 29.04
Trevena, Inc. 19.99 9.13 -56.25 -421.38
Acorda Therapeutics, Inc. 32.11 2.39 -0.59 6.4
Eiger BioPharmaceuticals, Inc. 24.03 12.09 -66.84 -279.22
Array BioPharma Inc. 9.11 3.47 -8.2 -70.39
ArQule, Inc. 27.46 5.33 -76.21 -325.34
Amgen Inc. 28.81 6.2 7.78 30.26
Cytokinetics, Incorporated 25.92 5.73 0.56 18.65
Peer Median 22.01 5.53 -0.02 12.52
Best In Class 9.11 12.09 No interest exp 999

Looking for more metrics and analysis for Cytokinetics, Inc.?

Company Profile

Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.


The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website